XML 58 R49.htm IDEA: XBRL DOCUMENT
v3.24.0.1

Co-Development Agreement with SFJ Pharmaceuticals and Development Derivative Liability - Additional Information (Details) - SFJ | Feb. 12, 2021 USD ($)
--- | ---
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |
Committed funding (up to) | $ 150,000,000
Collaborative arrangement, success-based payments | $ 637,500,000

X
- Definition Collaborative Arrangement, Committed Funding + References No definition available. + Details
Name: | nktr_CollaborativeArrangementCommittedFunding
Namespace Prefix: | nktr_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Collaborative Arrangement, Success-Based Payments, Amount + References No definition available. + Details
Name: | nktr_CollaborativeArrangementSuccessBasedPaymentsAmount
Namespace Prefix: | nktr_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 808 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1 + Details
Name: | us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | srt_CounterpartyNameAxis=nktr_SFJPharmaceuticalsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |